-

Xeris to Participate in Upcoming Investor Conferences

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will take part in the following events:

  • 2024 Wells Fargo Healthcare Conference, Boston, MA
    • Meetings only on September 4, 2024
  • H.C. Wainwright 26th Annual Global Investor Conference, New York, NY
    • Meetings and fireside chat on September 10, 2024 at 3:30pm ET
  • 2024 Cantor Global Healthcare Conference, New York, NY
    • Meetings only on September 18, 2024

Please check with each conference sponsor to arrange 1x1 meetings.

Webcast information for the fireside chat will be available at https://xerispharma.com/investor-relations.

About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, a proven therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris has a pipeline of development and partnered programs using its formulation sciences, XeriSol™ and XeriJect®, to support long-term product development and commercial success.

Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow Xeris on Twitter, LinkedIn or Instagram.

Contacts

Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com

Industry:

Xeris Biopharma Holdings, Inc.

NASDAQ:XERS
Release Versions
English
Hashtags
#GvokeHypoPen
#T1D
#T2D

Contacts

Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com

More News From Xeris Biopharma Holdings, Inc.

Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025, and other highlights. "Our fourth quarter performance capped off a truly transformative 2025. Recorlev® delivered exceptional results, outperforming expectations and further strengthening the momentum our team built throughout the year,” said John Shannon, Chief Executive Officer. “When combined with the stellar contribution...

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on January 2, 2026, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 181,550 shares of its common stock to 50 new employee(s) under Xeris’ Inducement Equity Plan. Xeris’ Inducement Equit...

Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its subsidiary Xeris Pharmaceuticals Inc.’s U.S. patent application covering XP-8121, one of its novel product candidates. The Notice of Allowance indica...
Back to Newsroom